

FORM PTO-1390
(REV. 11-2000) modified

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S CHECK NUMBER

3056 USOP

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/516705

INTERNATIONAL APPLICATION NO.
PCT/JP03/06942INTERNATIONAL FILING DATE
June 2, 2003PRIORITY DATE CLAIMED
June 3, 2002

TITLE OF INVENTION

MUTANT ANDROGEN RECEPTOR, CANCER CELLS EXPRESSING THE SAME, A METHOD OF PRODUCING THEM AND USE THEREOF

APPLICANT(S) FOR DO/EO/US

Takahito HARA; Masami KUSAKA; Junichi MIYAZAKI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Cited References
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Itemized Return Postcard; Certificate of Express Mailing;
 PCT Request; Cover Page International Application; ISR;
 Forms PCT/IB/301, 304, 308, 332

Express Mail Label No. EV 524906671 US
 Date of Deposit December 2, 2004

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/516705		INTERNATIONAL APPLICATION NO. PCT/JP03/06942		ATTORNEY'S DOCKET NUMBER 056 USOP	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1110.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$950.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$790.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$750.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	70 - 20 =	50	x \$18.00	\$	900.00
Independent claims	12 - 3 =	9	x \$88.00	\$	792.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$300.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	2,642.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$	2,642.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	2,642.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	40.00
TOTAL FEES ENCLOSED =				\$	2,682.00
				Amount to be refunded:	\$
				charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>500799</u> in the amount of \$ <u>2,682.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>500799</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Mark Chao, PhD, JD Takeda Pharmaceuticals North America, Inc. 475 Half Day Road Lincolnshire, IL 60069 USA (847)383-3391 fax (847)383-3409					
				 SIGNATURE Mark Chao, PhD, JD NAME 43,032 REGISTRATION NUMBER For Customer No. 23,115	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	Based on PCT/JP03/06942	Art Unit:	tba
Filed:	Intl. Filing 02 JUNE 2003	Examiner:	tba
1 st Inventor:	Takahito HARA	Allowed:	
For:	Mutant Androgen Receptor, Cancer Cells Expressing the Same, A Method of Producing Them and Use Thereof	Batch:	
Atty. Dkt. No.	3056 USOP	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 524906671 US

DATE IN: December 2, 2004

Itemized Papers/Items:


1. This Certificate and Return Postcard (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Specification - total pages (92 including Claims 1-66 (pages 82-89), Abstract (1 page), and Drawings (3 pages)
4. PCT Request (6 pages)
5. Declaration and Power of Attorney (4 pages)
6. Copies of Forms PCT/IB/301, 304, 308, 332 (6 pages)
7. Copy of Cover Page International Application (WO 03/102188) (1 page)
8. Copy of International Search Report (4 pages)
9. Preliminary Amendment (15 pages)
10. Information Disclosure Statement (1 page), Form PTO/SB/08A & 08B 2 pages, cited references (9)
11. Submission of Sequence Listing Requirements (1 page), CRF of Sequence Listing (7 pages), and IBM PC/AT format disk containing the CRF of the Sequence Listing
12. Executed Assignment (2 pages) and Recordation Cover Sheet (1 page X 2)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT
P.O. BOX 1450
Commissioner for Patents
Alexandria, VA 22313-1450

on this date, 12/2/04

Dated: 12/2/04


Gail L. Winokur